Algernon Pharmaceuticals Inc. V.AGN

Primary Symbol: C.AGN Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by skinner3on Nov 26, 2003 7:04am

174 Views

Post# 6699895

left behind

What in the hell is going on did we get left behind again.While the juniors are racing ahead this dog with fleas will not even roll over.When are these results suppose to come out does anybody know.Noticed bza is picking up steam again.O'well maybe one day this will show some life.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China